Reportstack has announced a new market research publication on PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - UK Drug Forecast and Market Analysis to 2022. Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.
Scope
- Overview of SLE-LN including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting UK SLE-LN market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in UK
Scope
- Overview of SLE-LN including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting UK SLE-LN market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in UK
To view the table of contents and know more details please visit PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - UK Drug Forecast and Market Analysis to 2022.
No comments:
Post a Comment